Aptose Biosciences Files Routine 8-K on Jan 31, 2024
Ticker: APTOF · Form: 8-K · Filed: Jan 31, 2024 · CIK: 882361
Complexity: simple
Sentiment: neutral
Topics: compliance, regulatory-filing
TL;DR
**Aptose Biosciences filed a routine 8-K, no new material info.**
AI Summary
Aptose Biosciences Inc. filed an 8-K on January 31, 2024, indicating a routine current report filing. This filing doesn't contain specific financial or operational news, but rather serves as a general disclosure under Regulation FD and for financial statements and exhibits. For investors, this means there's no immediate new information impacting the stock price, but it's a standard compliance filing that confirms the company is meeting its reporting obligations.
Why It Matters
This filing is a standard compliance report, not a news event. It signals that Aptose Biosciences is adhering to SEC regulations, which is important for maintaining investor confidence and transparency.
Risk Assessment
Risk Level: low — This 8-K is a standard, non-event filing and does not introduce new risks or changes to the company's operational or financial standing.
Analyst Insight
A smart investor would note this as a routine compliance filing, indicating no immediate new information to act upon. It's a 'no news is good news' scenario, confirming the company's adherence to regulatory requirements.
Key Players & Entities
- Aptose Biosciences Inc. (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of earliest event reported and filing date
- 001-32001 (other) — Commission File Number for Aptose Biosciences Inc.
- 251 Consumers Road, Suite 1105 Toronto, Ontario M2J 4R3 Canada (other) — principal executive offices address of Aptose Biosciences Inc.
FAQ
What is the purpose of this specific 8-K filing by Aptose Biosciences Inc.?
This 8-K filing by Aptose Biosciences Inc. is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'. It's a routine compliance filing.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 31, 2024.
What is the business address of Aptose Biosciences Inc. as stated in the filing?
The business address of Aptose Biosciences Inc. is 251 Consumers Road, Suite 1105, Toronto, Ontario M2J 4R3, Canada.
What is the Commission File Number for Aptose Biosciences Inc.?
The Commission File Number for Aptose Biosciences Inc. is 001-32001.
Does this 8-K filing contain any specific financial or operational updates?
Based on the provided text, this 8-K filing is a general current report and does not detail specific financial or operational updates, new agreements, or material events beyond its classification under Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-01-31 16:02:15
Filing Documents
- f8k_013124.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-24-000488.txt ( ) — 222KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_013124_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On January 31, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated January 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: January 31, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer